Alpha 2.0
Login Register
» Authors » Yukichi Tanaka

Yukichi Tanaka

Explore the profile of Yukichi Tanaka including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 134
Citations 2016
Followers 0
Related Specialties
Pediatrics
Oncology
Pathology
Top 10 Co-Authors
Mio Tanaka
Keisuke Kato
Noriko Aida
Norihiko Kitagawa
Hisato Kigasawa
Eiso Hiyama
Kenji Kurosawa
Rieko Ijiri
Junko Takita
Tomoro Hishiki
Published In
Pediatr Blood Cancer
Pathol Int
J Pediatr Surg
Hum Pathol
Pediatr Surg Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Two-hit mutation causes Wilms tumor in an individual with FBXW7-related neurodevelopmental syndrome
Saito Y, Keino D, Kuroda Y, Enomoto Y, Naruto T, Tanaka Y, et al.
J Hum Genet . 2024 Oct; 70(2):121-123. PMID: 39414990
FBXW7 (F-box and WD-repeat domain-containing 7) is a tumor suppressor gene, and its germline variants have been causally linked to Wilms tumors. Furthermore, germline variants of FBXW7 have also been...
2.
Establishment and Characterization of a Novel Pleuropulmonary Blastoma Cell Line
Kato K, Goto H, Tanaka M, Suzuki T, Toyoda Y, Shinkai M, et al.
Genes Chromosomes Cancer . 2024 Oct; 63(10):e23276. PMID: 39400393
Purpose: Pleuropulmonary blastoma (PPB) is an infrequently encountered childhood malignant intrathoracic neoplasm associated with unfavorable clinical behavior. Since a well-characterized preclinical model is essential for developing competent agents for PPB,...
3.
Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children's hepatic tumors international collaboration database
Hiyama E, Hishiki T, Yoshimura K, Krailo M, Maibach R, Haeberle B, et al.
EClinicalMedicine . 2024 Sep; 76:102811. PMID: 39309724
Background: In the treatment of resectable hepatoblastoma (HB), it has not been established whether upfront surgery (UF) at diagnosis or neoadjuvant chemotherapy and delayed surgery (DL) is preferred. We compared...
4.
Successful treatment of young childhood standard-risk hepatoblastoma with cisplatin monotherapy using a central review system
Saeki I, Ida K, Kurihara S, Watanabe K, Mori M, Hishiki T, et al.
Pediatr Blood Cancer . 2024 Aug; 71(11):e31255. PMID: 39126361
Background: The JPLT3-S (Japanese Study Group for Pediatric Liver Tumors-3) study, conducted cisplatin (CDDP) monotherapy for young children (<3 years old) with standard-risk hepatoblastoma (HB) using a central review system...
5.
Establishment and characterization of a novel MDM2/MYCN-co-amplified neuroblastoma cell line, NBN-SHIM, established from a late recurrent stage MS tumor
Kato K, Nagai J, Goto H, Shinkai M, Kitagawa N, Toyoda Y, et al.
Hum Cell . 2024 Jul; 37(5):1602-1609. PMID: 39080217
The biological heterogeneity of neuroblastoma underscores the need for an in vitro model of each molecularly defined subgroup to investigate tumorigenesis and develop targeted therapies. We have established a permanently...
6.
Localized anaplastic lymphoma kinase-positive histiocytosis in a cerebellar hemisphere with long-term treatment: illustrative case
Kumagai E, Tanaka M, Iwasaki F, Yanagimachi M, Hirokawa D, Goto H, et al.
J Neurosurg Case Lessons . 2024 May; 7(22). PMID: 38801782
Background: Anaplastic lymphoma kinase (ALK)-positive histiocytosis (ALK-H) is an emerging entity in the category of histiocytic neoplasms that was first reported as a multisystemic disease in three infants in 2008....
7.
Metronomic Chemotherapy for Pediatric Refractory Solid Tumors: A Retrospective Single-center Study
Sakurai Y, Iwasaki F, Hirose A, Matsumoto N, Miyagawa N, Keino D, et al.
J Pediatr Hematol Oncol . 2024 May; 46(5):233-240. PMID: 38691057
Metronomic chemotherapy (MC) is based on chronic administration of chemotherapeutic agents at minimally toxic doses without prolonged drug-free breaks, that inhibits tumor angiogenesis and induces tumor dormancy. This study aimed...
8.
Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC)
Cho S, Ranganathan S, Alaggio R, Maibach R, Tanaka Y, Inoue T, et al.
Pediatr Blood Cancer . 2023 Jun; :e30505. PMID: 37384428
Background: Liver tumors are rare in children with histologic heterogeneity that makes diagnosis challenging. Systematic histopathological review, performed as part of collaborative therapeutic protocols, identified relevant histologic subtypes that are...
9.
Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children's Hepatic Tumors International Collaboration (CHIC)
Trobaugh-Lotrario A, Maibach R, Aronson D, Rangaswami A, Haberle B, ONeill A, et al.
Cancers (Basel) . 2023 Jan; 15(2). PMID: 36672416
Small cell undifferentiated (SCU) histology and alpha-fetoprotein (AFP) levels below 100 ng/mL have been reported as poor prognostic factors in hepatoblastoma (HB); subsequent studies reported mutations in some SCU HBs...
10.
Infantile hepatic hemangioma and hepatic mesenchymal hamartoma in an infant associated with placental mesenchymal dysplasia: a case report
Fujii S, Mochizuki K, Usui H, Kitagawa N, Umemoto S, Tanaka M, et al.
Surg Case Rep . 2022 Aug; 8(1):161. PMID: 36031652
Background: Although infantile hepatic hemangioma and hepatic mesenchymal hamartoma are relatively common in benign pediatric liver tumors, coexistence of the two tumors is rare. Placental mesenchymal dysplasia is also a...